Firsov A A, Nasonov V N
National Research Institute of Antibiotics, Moscow, USSR.
Eur J Drug Metab Pharmacokinet. 1991;Spec No 3:327-31.
Amikacin pharmacokinetics was studied in 20 critically ill patients after a single i.v. bolus dose (500 mg). The amikacin pharmacokinetic profiles were characterized by marked intra-individual variability. Stepwise multivariate regression analysis made it possible to establish statistically significant correlations between the amikacin total clearance (Cl) and 8 patient's factors such as the, age, sodium plasma content, plasma osmolarity, partial pressure of oxygen and carbon dioxide, volumes of transfused plasma and blood, application of artificial lung ventilation (r2 = 0.98). The multiple regression equation for the Cl prediction provides reliable indirect estimation of the parameter. Thus, it appears possible to adjust the aminoglycoside dosage by taking into account 8 patient's factors, until the amikacin plasma concentration, time data are available.
对20例危重症患者单次静脉推注500毫克阿米卡星后的药代动力学进行了研究。阿米卡星的药代动力学特征表现为个体内差异显著。逐步多元回归分析使得能够在阿米卡星总清除率（Cl）与8个患者因素（如年龄、血浆钠含量、血浆渗透压、氧分压和二氧化碳分压、输注血浆和血液的量、人工肺通气的应用）之间建立具有统计学意义的相关性（r2 = 0.98）。用于预测Cl的多元回归方程为该参数提供了可靠的间接估计。因此，在获得阿米卡星血浆浓度-时间数据之前，似乎可以通过考虑8个患者因素来调整氨基糖苷类药物的剂量。
